Objective: To observe the effects of Shuxuening injection on serum vascular endothelial growth factor (VEGF)

plasma von Willebrand factor (vWF) and matrix metalloproteinase-9 (MMP-9) in patients with acute cerebral infarction (ACI). Method: Eighty subjects with ACI were randomly divided into observation group (n=40) and control group (n=40). Both groups were received conventional treatment. The control group was given edaravone 30 mg ivgtt

bid; the observation group was given Shuxuening injection 25 mL ivgtt. qd

all for 14 days. The level of VEGF

vWF and MMP-9 were observed by enzyme-linked immunosorbent assay (ELISA) and neurologic function was evaluated. Result: The post-treatment NHISS scores of both groups showed a declining curve

the NHISS score of the observation group at 14 day was lower than that in the control group (P<0.05). The post-treatment neurological function evaluation of the observation group was superior to the control group (P<0.05). The level of serum VEGF of the observation group at 14 day was higher than the control group (P<0.05)

the level of vWF and MMP-9 in the observation group was lower than those in the control group (P<0.05

P<0.01). Conclusion: Shuxuening injection can improve neurologic impairment of patients with ACI

the mechanism may be related to the levels of VEGF

vWF and MMP-9.